First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations.

摘要: While the small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors erlotinib and gefitinib have modest clinical benefit in unselected patients with non-small cell lung cancer after platinum-based chemotherapy, an emerging potentially more elegant strategy is to move these agents frontline setting for select patients. Those somatic mutations EGFR respond dramatically inhibitors, mounting evidence from recent trials, particularly Iressa Pan-Asia Study (IPASS) trial, confirms superior response rates, progression-free survival, tolerability this targeted therapy compared conventional chemotherapy. Here, we review studies supporting use of mutations.